The BIOKÉ webshop is closed until January 2nd, 2019. We wish you a successful 2019!
LEIDEN, October 24, 2016 - BIOKÉ, a Cell Signaling Technology Europe (CST Europe) company, and ACEA Biosciences, Inc., a high performance cell analysis platforms manufacturer, announced their partnership to exclusively distribute ACEA’s NovoCyte™ Flow Cytometer in the BeNeLux countries, effective immediately.
The NovoCyte Flow Cytometer is a high performance benchtop flow cytometer designed for all levels of users and all types of laboratories at easily attainable investment cost. The system addresses a wide range of multi-parameter cellular analysis research needs (up to 15 parameters) with its flexible, customizable detection configurations, intuitive acquisition, user-friendly analysis software, and walkaway capabilities. The system uses a highly accurate, volumetric syringe pump which enables direct absolute counting of samples, eliminating the need to use expensive reference beads. The NovoCyte flow cytometer is available with up to three configurable laser options (including Blue, Yellow/Green, Violet and Red), exchangeable filters, and flexible analysis formats. User hands-on time is minimized by the flexible NovoSampler® Pro, a modular autosampler, which can automatically analyze samples in single tubes, multi-tube racks, or 24-, 48-, or 96-well plates.
It is a cytometer designed enabling all types of users focus more on their experiment, with intuitive features such as, automated maintenance functions, fixed PMTs, 24-bit 7.2 log dynamic range, and easy compensation tools.
“Flow cytometry is a powerful tool for cell analysis and yet the cost and complexity of systems can limit accessibility for researchers,” said Xiaobo Wang, Ph.D., Chief Technology Officer, ACEA Biosciences. “With the NovoCyte system, researchers have a new option to advance their studies with the best combination of performance, usability and cost.”
“The addition of the NovoCyte system enables BIOKÉ delivering a protein analysis workflow for customers existing of a high quality bench top instrument in combination the highest quality antibodies from Cell Signaling Technology”, said Koos Kranenborg, Director of Marketing & Sales – BIOKÉ.
BIOKÉ, founded in 2004, is a leading provider of Life Science and Diagnostics solutions in Europe. The young and dynamic company provides innovative, high-performance applications for genomics, proteomics, and molecular diagnostics. Since 2009, the office in Leiden, The Netherlands is the European base of operations of Cell Signaling Technology. With its technologies and equipment, BIOKÉ helps accelerate and improve diagnostics and research activities by enabling reproducible results. The company provides with customized solutions, including service support - not as a contractor, but as a knowledge partner. For additional information please visit the BIOKÉ website at www.bioke.com
About ACEA Biosciences
Founded in 2002, ACEA Biosciences, Inc. (ACEA) is a privately held biotechnology company pioneering in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. With headquarters in San Diego, CA, ACEA has developed proprietary technology and launched its first product in 2004. Researchers are advancing their studies utilizing 1,700+ placed instruments for broad and diverse applications. The technology has been cited in over 700 peer-reviewed publications. ACEA’s xCELLigence® Real-Time Cell Analysis and NovoCyte™ Bench-Top Flow Cytometer Systems are used in pre-clinical drug discovery and development, toxicity, safety pharmacology, and basic academic research. Visit www.aceabio.com to learn more.